Mumbai, Baltimore, January 6, 2021: Lupin Limited (Lupin), global pharmaceutical company, announced today that it has received approval for its Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, from the United States Food and Drug Administration, to market a generic equivalent of Bactrim Oral Suspension, 200 mg/40 mg per 5 mL, of Sun Pharmaceutical Industries, Inc.
Sulfamethoxazole and Trimethoprim Oral Suspension USP, 200 mg/40 mg per 5 mL, is indicated for the treatment and prevention of a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections), and certain type of pneumonia (pneumocystis-type).
Sulfamethoxazole and Trimethoprim Oral Suspension USP (RLD: Bactrim) had estimated annual sales of approximately USD 19 million in the U.S. (IQVIA MAT September 2020).
Are you an aspiring enthusiast willing to develop a career in the medical sales field? The dynamic profile of a medical representative, their exponent...
A healthy gut indicates a healthy you! Isn't that true? In easy words, gut health refers to the balance of microorganisms present in your digestive sy...
Is the scorching sun heat taking a toll on your skin health? The summers trigger all skin types due to excessive humidity and heat around. Dermatologi...
